The U.S. Food and Drug Administration (FDA) on Thursday extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for Cytokinetics Inc's (NASDAQ:CYTK) aficamten for patients with obstructive hypertrophic cardiomyopathy (oHCM) to December 26 from…